8legs: Dana-farber cancer institute

#1 out of 1100.00%

New pancreatic cancer pill could reshape treatment as early trial results stun researchers

Recent early-stage trial shows daraxonrasib achieving disease control in about 90% of metastatic pancreatic cancer patients with RAS mutations.
Around 30% of participants at the 300-milligram dose showed a positive tumor response in the trial.
The study was not randomized, so it cannot prove that daraxonrasib is better than standard chemotherapy.
Lead investigator Dr. Brian Wolpin cautioned that larger trials are needed to confirm efficacy and safety.
The trial enrolled 168 patients with RAS-mutant metastatic pancreatic cancer who had prior chemotherapy.
Wolpin described daraxonrasib as a potential shift in pancreatic cancer care pending further validation.
Common side effects included rash, mouth inflammation, nausea, and diarrhea, but most patients tolerated treatment with supportive care.
The drug targets multiple cancer signals linked to the RAS gene, potentially addressing a broad set of pancreatic cancers.
Experts say further research is needed to determine optimal sequencing or combination therapies.
The findings were published in The New England Journal of Medicine and presented by the Dana-Farber Cancer Institute researchers.

Vote 0